Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 7, 2014, Pages 960-968

  McClune, Brian L ^a   Ahn, Kwang Woo ^b   Wang, Hai Lin ^b   Antin, Joseph H ^c   Artz, Andrew S ^d   Cahn, Jean Yves ^e   Deol, Abhinav ^f   Freytes, César O ^g   Hamadani, Mehdi ^b   Holmberg, Leona A ^h   Jagasia, Madan H ⁱ   Jakubowski, Ann A ^j   Kharfan Dabaja, Mohamed A ^k   Lazarus, Hillard M ^l   Miller, Alan M ^m   Olsson, Richard ^n,o   Pedersen, Tanya L ^p   Pidala, Joseph ^k   Pulsipher, Michael A ^q   Rowe, Jacob M ^r   Saber, Wael ^b   van Besien, Koen W ^s   Waller, Edmund K ^t   Aljurf, Mahmoud D ^u   Akpek, Görgun ^v   Bacher, Ulrike ^w,x   Chao, Nelson J ^y   Chen, Yi Bin ^z   Cooper, Brenda W ^l   Dehn, Jason ^aa   de Lima, Marcos J ^l   Hsu, Jack W ^ab   Lewis, Ian D ^ac   Marks, David I ^ad   McGuirk, Joseph ^ae   Cairo, Mitchell S ^af   Schouten, Harry C ^ag   Szer, Jeffrey ^ah   Ramanathan, Muthalagu ^ai   Savani, Bipin N ⁱ   Seftel, Matthew ^aj   Socie, Gérard ^ak   Vij, Ravi ^al   Warlick, Erica D ^a   Weisdorf, Daniel J ^a   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f WAYNE STATE UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^l UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^m BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁿ KAROLINSKA INSTITUTE   (Sweden)

^o UPPSALA UNIVERSITY   (Sweden)

^p Center for International Blood and Marrow Transplant Research   (United States)

^q UNIVERSITY OF UTAH   (United States)

^r RAMBAM MEDICAL CENTER   (Israel)

^s WEILL CORNELL MEDICAL COLLEGE   (United States)

^t EMORY UNIVERSITY HOSPITAL   (United States)

^u KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^v Banner MD Anderson Cancer Center   (United States)

^w UNIVERSITY OF HAMBURG   (Germany)

^x MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^y DUKE UNIVERSITY MEDICAL CENTER   (United States)

^z MASSACHUSETTS GENERAL HOSPITAL   (United States)

^aa NATIONAL MARROW DONOR PROGRAM   (United States)

^ab UNIVERSITY OF FLORIDA   (United States)

^ac ROYAL ADELAIDE HOSPITAL   (Australia)

^ad BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^ae UNIVERSITY OF KANSAS   (United States)

^af NEW YORK MEDICAL COLLEGE   (United States)

^ag MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^ah ROYAL MELBOURNE HOSPITAL   (Australia)

^ai UMASS MEMORIAL MEDICAL CENTER   (United States)

^aj PRINCESS MARGARET HOSPITAL   (Canada)

^ak SAINT LOUIS HOSPITAL   (France)

^al BARNES JEWISH HOSPITAL   (United States)

more..

Author keywords

Allogeneic; Elderly; Hematopoietic cell transplantation; Lymphoma; Nonmyeloablative; Reduced intensity

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; TACROLIMUS; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL TRANSPLANTATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; WHOLE BODY RADIATION; AGE; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; PROCEDURES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

ADULT; AGE FACTORS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84902120179     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.03.013     Document Type: Article

References (37)

1. Jantunen E., Sureda A. The evolving role of stem cell transplants in lymphomas. Biol Blood Marrow Transplant 2012, 18:660-673.
2. Thieblemont C., Coiffier B. Lymphoma in older patients. J Clin Oncol 2007, 25:1916-1923.
3. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Long term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011, 306:1874-1883.
4. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310-4316.
5. Rezvani A.R., Storer B., Maris M., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:211-217.
6. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
7. Tomblyn M., Brunstein C., Burns L.J., et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:538-545.
8. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010, 28:1878-1887.
9. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
10. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2009, 15:367-369.
11. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
12. Champlin R., Khouri I., Shimoni A., et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000, 111:18-29.
13. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
14. Arai S., Jagasia M., Storer B., et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011, 118:4242-4249.
15. Andersen P., Klein J., Rosthoj S. Generalized linear models for correlated pseudo-observations, with applications to multi-state models. Biometrika 2003, 90:15-27.
16. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004, 104:1923-1930.
17. Hari P., Carreras J., Zhang M.J., et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008, 14:236-245.
18. Freytes C.O., Zhang M.J., Carreras J., et al. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant 2012, 18:1255-1264.
19. Rigacci L., Puccini B., Dodero A., et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol 2012, 91:931-939.
20. Soiffer R.J., LeRademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
21. van Besien K., Carreras J., Bierman P.J., et al. Unrelated donor hematopoietic cell transplantation for non-Hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009, 15:554-563.
22. Hale G.A., Shrestha S., Le-Rademacher J., et al. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower-intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant 2012, 18:1036-1043.
23. Thomson K.J., Morris E.M., Bloor A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 27:426-432.
24. Rodriguez R., Nademanee A., Ruel N., et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1326-1334.
25. Vose J.M., Bierman P.J., Anderson J.R., et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992, 80:2142-2148.
26. Kewalramani T., Nimer S.D., Zelenetz A.D., et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003, 32:673-679.
27. Hamlin P.A., Zelenetz A.D., Kewalramani T., et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003, 102:1989-1996.
28. Dietrich S., Tielesch B., Rieger M., et al. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer 2011, 117:1901-1910.
29. Elstrom R.L., Martin P., Ostrow K., et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk 2010, 10:192-196.
30. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations). Available from: Accessed April 2013. http://seer.cancer.gov/csr/1975_2009_pops09/.
31. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
32. van Kampen R.J., Canals C., Schouten H.C., et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011, 29:1342-1348.
33. Bacher U., Klyuchnikov E., Le-Rademacher J., et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced-intensity?. Blood 2012, 120:4256-4262.
34. Calderón-Cabrera C., Márquez-Malaver F.J., de la Cruz-Vicente F., et al. Improvement over the years of long-term survival in high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy. Transplant Proc 2013, 45:3665-3667.
35. Hahn T., McCarthy P.L., Hassebroek A., et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013, 31:2437-2449.
36. Wondergem M.J., Dijkstra F.S., Visser O.J., et al. Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies. Bone Marrow Transplant 2014, 10.1038/bmt.2013.221.
37. Fenske T.S., Zhang M.J., Carreras J., et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 2013, 10.1200/JCO.2013.49.2454.